Phase I/II, open-label, multicenter, multi-part, dose escalation and dose expansion study to evaluate the safety, pharmacokinetic (PK), pharmacodynamics, and efficacy of rilvegostomig in adult participants with stage III unresectable or stage IV NSCLC

Rilvegostomig (Anti-TIGIT/Anti-PD-1 Bispecific Antibody)

• stage IV squamous NSCLC, PD-L1 TPS ≥ 1%
• No prior treatment for metastatic NSCLC
• ECOG 0-1

• Symptomatic central nervous system (CNS) metastasis.
• Thromboembolic event within 3 months before the first dose of investigational product.
• History of organ transplant.
• Active primary immunodeficiency/active infectious disease(s)
• History of arrhythmia or uncontrolled intercurrent illness
• Other invasive malignancy within 2 years prior to screening